|
1
|
Xu D, Guo H, Xu X, Lu Z, Fassett J, Hu X,
Xu Y, Tang Q, Hu D, Somani A, et al: Exacerbated pulmonary arterial
hypertension and right ventricular hypertrophy in animals with loss
of function of extracellular superoxide dismutase. Hypertension.
58:303–309. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Provencher S and Granton JT: Current
treatment approaches to pulmonary arterial hypertension. Can J
Cardiol. 31:460–477. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vachiery JL and Gaine S: Challenges in the
diagnosis and treatment of pulmonary arterial hypertension. Eur
Respir Rev. 21:313–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rozec B and Gauthier C:
Beta3-adrenoceptors in the cardiovascular system: Putative roles in
human pathologies. Pharmacol Ther. 111:652–673. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moens AL, Yang R, Watts VL and Barouch LA:
Beta 3-adrenoreceptor regulation of nitric oxide in the
cardiovascular system. J Mol Cell Cardiol. 48:1088–1095. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gauthier C, Tavernier G, Charpentier F,
Langin D and Le Marec H: Functional beta3-adrenoceptor in the human
heart. J Clin Invest. 98:556–562. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niu X, Watts VL, Cingolani OH, Sivakumaran
V, Leyton-Mange JS, Ellis CL, Miller KL, Vandegaer K, Bedja D,
Gabrielson KL, et al: Cardioprotective effect of beta-3 adrenergic
receptor agonism: Role of neuronal nitric oxide synthase. J Am Coll
Cardiol. 59:1979–1987. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tavernier G, Toumaniantz G, Erfanian M,
Heymann MF, Laurent K, Langin D and Gauthier C: Beta3-Adrenergic
stimulation produces a decrease of cardiac contractility ex vivo in
mice overexpressing the human beta3-adrenergic receptor. Cardiovasc
Res. 59:288–296. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao Q, Zeng F, Liu JB, He Y, Li B, Jiang
ZF, Wu TG and Wang LX: Upregulation of β3-adrenergic receptor
expression in the atrium of rats with chronic heart failure. J
Cardiovasc Pharmacol Ther. 18:133–137. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gauthier C, Langin D and Balligand JL:
Beta3-adrenoceptors in the cardiovascular system. Trends Pharmacol
Sci. 21:426–431. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bhadada SV, Patel BM, Mehta AA and Goyal
RK: β(3) Receptors: Role in cardiometabolic disorders. Ther Adv
Endocrinol Metab. 2:65–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rasmussen HH, Figtree GA, Krum H and
Bundgaard H: The use of beta3-adrenergic receptor agonists in the
treatment of heart failure. Curr Opin Investig Drugs. 10:955–962.
2009.PubMed/NCBI
|
|
13
|
Feng MG, Prieto MC and Navar LG:
Nebivolol-induced vasodilation of renal afferent arterioles
involves beta3-adrenergic receptor and nitric oxide synthase
activation. Am J Physiol Renal Physiol. 303:F775–F782. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rozec B, Serpillon S, Toumaniantz G, Sèze
C, Rautureau Y, Baron O, Noireaud J and Gauthier C:
Characterization of beta3-adrenoceptors in human internal mammary
artery and putative involvement in coronary artery bypass
management. J Am Coll Cardiol. 46:351–359. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pietri-Rouxel F and Strosberg AD:
Pharmacological characteristics and species-related variations of
beta 3-adrenergic receptors. Fundam Clin Pharmacol. 9:211–218.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moniotte S and Balligand JL: Potential use
of beta(3)-adrenoceptor antagonists in heart failure therapy.
Cardiovasc Drug Rev. 20:19–26. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pourageaud F, Leblais V, Bellance N,
Marthan R and Muller B: Role of beta2-adrenoceptors (beta-AR), but
not beta1-, beta3-AR and endothelial nitric oxide, in
beta-AR-mediated relaxation of rat intrapulmonary artery. Naunyn
Schmiedebergs Arch Pharmacol. 372:14–23. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tagaya E, Tamaoki J, Takemura H, Isono K
and Nagai A: Atypical adrenoceptor-mediated relaxation of canine
pulmonary artery through a cyclic adenosine monophosphate-dependent
pathway. Lung. 177:321–332. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu Y, Fuscoe JC, Zhao C, Guo C, Jia M,
Qing T, Bannon DI, Lancashire L, Bao W, Du T, et al: A rat RNA-Seq
transcriptomic BodyMap across 11 organs and 4 developmental stages.
Nat Commun. 5:32302014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
García-Aívarez A, Pereda D, Garcia-Lunar
I, Sanz-Rosa D, Fernández-Jiménez R, García-Prieto J, Nuño-Ayala M,
Sierra F, Santiago E, Sandoval E, et al: Beta-3 adrenergic agonists
reduce pulmonary vascular resistance and improve right ventricular
performance in a porcine model of chronic pulmonary hypertension.
Basic Res Cardiol. 111:492016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Perros F, Ranchoux B, Izikki M, Bentebbal
S, Happé C, Antigny F, Jourdon P, Dorfmüller P, Lecerf F, Fadel E,
et al: Nebivolol for improving endothelial dysfunction, pulmonary
vascular remodeling and right heart function in pulmonary
hypertension. J Am Coll Cardiol. 65:668–680. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pott C, Brixius K, Bundkirchen A, Bölck B,
Bloch W, Steinritz D, Mehlhorn U and Schwinger RH: The preferential
beta3-adrenoceptor agonist BRL 37344 increases force via
beta1-/beta2-adrenoceptors and induces endothelial nitric oxide
synthase via beta3-adrenoceptors in human atrial myocardium. Br J
Pharmacol. 138:521–529. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hicks A, McCafferty GP, Riedel E, Aiyar N,
Pullen M, Evans C, Luce TD, Coatney RW, Rivera GC, Westfall TD and
Hieble JP: GW427353 (solabegron), a novel, selective
beta3-adrenergic receptor agonist, evokes bladder relaxation and
increases micturition reflex threshold in the dog. J Pharmacol Exp
Ther. 323:202–209. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pankey EA, Edward JA, Swan KW, Bourgeois
CR, Bartow MJ, Yoo D, Peak TA, Song BM, Chan RA, Murthy SN, et al:
Nebivolol has a beneficial effect in monocrotaline-induced
pulmonary hypertension. Can J Physiol Pharmacol. 94:758–768. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gan RT, Li WM, Wang X, Wu S and Kong YH:
Effect of beta3-adrenoceptor antagonist on the cardiac function and
expression of endothelial nitric oxide synthase in a rat model of
heart failure. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 19:675–678.
2007.(In Chinese). PubMed/NCBI
|
|
26
|
Wang Y, Li Z, Zhang Y, Yang W, Sun J, Shan
L and Li W: Targeting Pin1 protects mouse cardiomyocytes from
high-dose alcohol-induced apoptosis. Oxid Med Cell Longev.
2016:45289062016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guide for the Care and Use of Laboratory
Animals. th (ed). Washington (DC): 2011, PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schultze AE and Roth RA: Chronic pulmonary
hypertension-the monocrotaline model and involvement of the
hemostatic system. J Toxicol Environ Health B Crit Rev. 1:271–346.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rudski LG, Lai WW, Afilalo J, Hua L,
Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK and
Schiller NB: Guidelines for the echocardiographic assessment of the
right heart in adults: A report from the American Society of
Echocardiography endorsed by the European Association of
Echocardiography, a registered branch of the European Society of
Cardiology and the Canadian Society of Echocardiography. J Am Soc
Echocardiogr. 23:685-713–quiz 786–788. 2010. View Article : Google Scholar
|
|
31
|
Bogaard HJ, Natarajan R, Mizuno S, Abbate
A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN
and Voelkel NF: Adrenergic receptor blockade reverses right heart
remodeling and dysfunction in pulmonary hypertensive rats. Am J
Respir Crit Care Med. 182:652–660. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Baker JG, Hill SJ and Summers RJ:
Evolution of β-blockers: From anti-anginal drugs to ligand-directed
signalling. Trends Pharmacol Sci. 32:227–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dessy C and Balligand JL: Beta3-adrenergic
receptors in cardiac and vascular tissues emerging concepts and
therapeutic perspectives. Adv Pharmacol. 59:135–163. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Strosberg AD: Structure and function of
the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol.
37:421–450. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cheng HJ, Zhang ZS, Onishi K, Ukai T, Sane
DC and Cheng CP: Upregulation of functional beta(3)-adrenergic
receptor in the failing canine myocardium. Circ Res. 89:599–606.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Morimoto A, Hasegawa H, Cheng HJ, Little
WC and Cheng CP: Endogenous beta3-adrenoreceptor activation
contributes to left ventricular and cardiomyocyte dysfunction in
heart failure. Am J Physiol Heart Circ Physiol. 286:H2425–H2433.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gan RT, Li WM, Xiu CH, Shen JX, Wang X, Wu
S and Kong YH: Chronic blocking of beta 3-adrenoceptor ameliorates
cardiac function in rat model of heart failure. Chin Med J (Engl).
120:2250–2255. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ursino MG, Vasina V, Raschi E, Crema F and
De Ponti F: The beta3-adrenoceptor as a therapeutic target: Current
perspectives. Pharmacol Res. 59:221–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hutchinson DS, Chernogubova E, Sato M,
Summers RJ and Bengtsson T: Agonist effects of zinterol at the
mouse and human beta(3)-adrenoceptor. Naunyn Schmiedebergs Arch
Pharmacol. 373:158–168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sato M, Horinouchi T, Hutchinson DS, Evans
BA and Summers RJ: Ligand-directed signaling at the
beta3-adrenoceptor produced by
3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapt-1-ylamino]-2S-2-propanol
oxalate (SR59230A) relative to receptor agonists. Mol Pharmacol.
72:1359–1368. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vrydag W and Michel MC: Tools to study
beta3-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol.
374:385–398. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Price LC, Wort SJ, Perros F, Dorfmüller P,
Huertas A, Montani D, Cohen-Kaminsky S and Humbert M: Inflammation
in pulmonary arterial hypertension. Chest. 141:210–221. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Steiner MK, Syrkina OL, Kolliputi N, Mark
EJ, Hales CA and Waxman AB: Interleukin-6 overexpression induces
pulmonary hypertension. Circ Res. 104:236–244. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mottillo EP, Shen XJ and Granneman JG:
Beta3-adrenergic receptor induction of adipocyte inflammation
requires lipolytic activation of stress kinases p38 and JNK.
Biochim Biophys Acta. 1801:1048–1055. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tchivileva IE, Tan KS, Gambarian M,
Nackley AG, Medvedev AV, Romanov S, Flood PM, Maixner W, Makarov SS
and Diatchenko L: Signaling pathways mediating beta3-adrenergic
receptor-induced production of interleukin-6 in adipocytes. Mol
Immunol. 46:2256–2266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mohamed-Ali V, Flower L, Sethi J,
Hotamisligil G, Gray R, Humphries SE, York DA and Pinkney J:
Beta-adrenergic regulation of IL-6 release from adipose tissue: In
vivo and in vitro studies. J Clin Endocrinol Metab. 86:5864–5869.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Haddad F, Doyle R, Murphy DJ and Hunt SA:
Right ventricular function in cardiovascular disease, part II:
Pathophysiology, clinical importance and management of right
ventricular failure. Circulation. 117:1717–1731. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sydykov A, Mamazhakypov A, Petrovic A,
Kosanovic D, Sarybaev AS, Weissmann N, Ghofrani HA and Schermuly
RT: Inflammatory mediators drive adverse right ventricular
remodeling and dysfunction and serve as potential biomarkers. Front
Physiol. 9:6092018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Klinger JR, Abman SH and Gladwin MT:
Nitric oxide deficiency and endothelial dysfunction in pulmonary
arterial hypertension. Am J Respir Crit Care Med. 188:639–646.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Roberts JD Jr, Roberts CT, Jones RC, Zapol
WM and Bloch KD: Continuous nitric oxide inhalation reduces
pulmonary arterial structural changes, right ventricular
hypertrophy and growth retardation in the hypoxic newborn rat. Circ
Res. 76:215–222. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Steudel W, Ichinose F, Huang PL, Hurford
WE, Jones RC, Bevan JA, Fishman MC and Zapol WM: Pulmonary
vasoconstriction and hypertension in mice with targeted disruption
of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res.
81:34–41. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fagan KA, Tyler RC, Sato K, Fouty BW,
Morris KG Jr, Huang PL, McMurtry IF and Rodman DM: Relative
contributions of endothelial, inducible and neuronal NOS to tone in
the murine pulmonary circulation. Am J Physiol. 277:L472–L478.
1999.PubMed/NCBI
|
|
53
|
Amour J, Loyer X, Le Guen M, Mabrouk N,
David JS, Camors E, Carusio N, Vivien B, Andriantsitohaina R,
Heymes C and Riou B: Altered contractile response due to increased
beta3-adrenoceptor stimulation in diabetic cardiomyopathy: The role
of nitric oxide synthase 1-derived nitric oxide. Anesthesiology.
107:452–460. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Maffei A, Di Pardo A, Carangi R, Carullo
P, Poulet R, Gentile MT, Vecchione C and Lembo G: Nebivolol induces
nitric oxide release in the heart through inducible nitric oxide
synthase activation. Hypertension. 50:652–656. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
d'Uscio LV: eNOS uncoupling in pulmonary
hypertension. Cardiovasc Res. 92:359–360. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Napp A, Brixius K, Pott C, Ziskoven C,
Boelck B, Mehlhorn U, Schwinger RH and Bloch W: Effects of the
beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide
synthase phosphorylation and force of contraction in human failing
myocardium. J Card Fail. 15:57–67. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nakazawa H, Hori M, Ozaki H and Karaki H:
Mechanisms underlying the impairment of endothelium-dependent
relaxation in the pulmonary artery of monocrotaline-induced
pulmonary hypertensive rats. Br J Pharmacol. 128:1098–1104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Seta F, Rahmani M, Turner PV and Funk CD:
Pulmonary oxidative stress is increased in cyclooxygenase-2
knockdown mice with mild pulmonary hypertension induced by
monocrotaline. PLoS One. 6:e234392011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Karbach S, Wenzel P, Waisman A, Munzel T
and Daiber A: eNOS uncoupling in cardiovascular diseases-the role
of oxidative stress and inflammation. Curr Pharm Des. 20:3579–3594.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Demarco VG, Whaley-Connell AT, Sowers JR,
Habibi J and Dellsperger KC: Contribution of oxidative stress to
pulmonary arterial hypertension. World J Cardiol. 2:316–324. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Francis BN, Salameh M, Khamisy-Farah R and
Farah R: Tetrahydrobiopterin (BH4): Targeting endothelial nitric
oxide synthase as a potential therapy for pulmonary hypertension.
Cardiovasc Ther. 36:2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Dorfmüller P, Chaumais MC, Giannakouli M,
Durand-Gasselin I, Raymond N, Fadel E, Mercier O, Charlotte F,
Montani D, Simonneau G, et al: Increased oxidative stress and
severe arterial remodeling induced by permanent high-flow challenge
in experimental pulmonary hypertension. Respir Res. 12:1192011.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Hampl V, BíbovBbová J, BanasovBbová A,
Uhlík J, Miková D, Hnilicková O, Lachmanová V and Herget J:
Pulmonary vascular iNOS induction participates in the onset of
chronic hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol
Physiol. 290:L11–L20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wang Y, Tian W, Xiu C, Yan M, Wang S and
Mei Y: Urantide improves the structure and function of right
ventricle as determined by echocardiography in
monocrotaline-induced pulmonary hypertension rat model. Clin
Rheumatol. 38:29–35. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kimura K, Daimon M, Morita H, Kawata T,
Nakao T, Okano T, Lee SL, Takenaka K, Nagai R, Yatomi Y and Komuro
I: Evaluation of right ventricle by speckle tracking and
conventional echocardiography in rats with right ventricular heart
failure. Int Heart J. 56:349–353. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Brixius K, Bloch W, Pott C, Napp A,
Krahwinkel A, Ziskoven C, Koriller M, Mehlhorn U, Hescheler J,
Fleischmann B and Schwinger RH: Mechanisms of beta
3-adrenoceptor-induced eNOS activation in right atrial and left
ventricular human myocardium. Br J Pharmacol. 143:1014–1022. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Brixius K, Bloch W, Ziskoven C, Bölck B,
Napp A, Pott C, Steinritz D, Jiminez M, Addicks K, Giacobino JP and
Schwinger RH: Beta3-adrenergic eNOS stimulation in left ventricular
murine myocardium. Can J Physiol Pharmacol. 84:1051–1060. 2006.
View Article : Google Scholar : PubMed/NCBI
|
